230 related articles for article (PubMed ID: 36469797)
1. Rates of Pheochromocytoma/Paraganglioma Screening in At-Risk Populations.
Grigoryan S; Nhan W; Zhang L; Urban C; Zhao L; Turcu AF
J Clin Endocrinol Metab; 2023 May; 108(6):e343-e349. PubMed ID: 36469797
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Cardiac Complications in Patients With Pheochromocytoma and Paraganglioma: A Retrospective Single-Center Study.
Zhao L; Meng X; Mei Q; Fan H; Liu Y; Zhou X; Zhu H; Zhang S
Front Endocrinol (Lausanne); 2022; 13():877341. PubMed ID: 35721724
[TBL] [Abstract][Full Text] [Related]
3. Seizures in patients with a phaeochromocytoma/paraganglioma (PPGL): A review of clinical cases and postulated pathological mechanisms.
Li Y; Zhang B
Rev Neurol (Paris); 2019 Oct; 175(9):495-505. PubMed ID: 31133278
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-based Study.
Ebbehoj A; Stochholm K; Jacobsen SF; Trolle C; Jepsen P; Robaczyk MG; Rasmussen ÅK; Feldt-Rasmussen U; Thomsen RW; Søndergaard E; Poulsen PL
J Clin Endocrinol Metab; 2021 Apr; 106(5):e2251-e2261. PubMed ID: 33479747
[TBL] [Abstract][Full Text] [Related]
5. Clinical diagnosis of pheochromocytoma and paraganglioma-induced secondary hypertension through UPLC-MS/MS analysis of plasma catecholamines and their metabolites.
Zhang W; Li X; Li W; Zhang Y; Cai J; Feng S; Sun Z
J Clin Hypertens (Greenwich); 2024 Apr; 26(4):416-424. PubMed ID: 38459755
[TBL] [Abstract][Full Text] [Related]
6. Pheochromocytomas and Paragangliomas.
Tevosian SG; Ghayee HK
Endocrinol Metab Clin North Am; 2019 Dec; 48(4):727-750. PubMed ID: 31655773
[TBL] [Abstract][Full Text] [Related]
7. The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.
Gruber LM; Jasim S; Ducharme-Smith A; Weingarten T; Young WF; Bancos I
J Clin Endocrinol Metab; 2021 May; 106(6):e2393-e2401. PubMed ID: 33693908
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma.
Li M; Prodanov T; Meuter L; Kerstens MN; Bechmann N; Prejbisz A; Remde H; Timmers HJLM; Nölting S; Talvacchio S; Berends AMA; Fliedner S; Robledo M; Lenders JWM; Pacak K; Eisenhofer G; Pamporaki C
J Clin Endocrinol Metab; 2023 Jan; 108(2):397-404. PubMed ID: 36190922
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas.
Al-Harthy M; Al-Harthy S; Al-Otieschan A; Velagapudi S; Alzahrani AS
Endocr Pract; 2009 Apr; 15(3):194-202. PubMed ID: 19364686
[TBL] [Abstract][Full Text] [Related]
10. [Presentations and management of adrenal hypertension].
Amar L; Lorthioir A; Giavarini A; Plouin PF; Azizi M
Presse Med; 2014 Apr; 43(4 Pt 1):420-7. PubMed ID: 24569318
[TBL] [Abstract][Full Text] [Related]
11. Clinical Presentation and Treatment Outcomes of Children and Adolescents With Pheochromocytoma and Paraganglioma in a Single Center in Korea.
Park H; Kim MS; Lee J; Kim JH; Jeong BC; Lee S; Lee SK; Cho SY; Jin DK
Front Endocrinol (Lausanne); 2020; 11():610746. PubMed ID: 33584544
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy and phaeochromocytoma/paraganglioma: clinical clues affecting diagnosis and outcome - a systematic review.
Langton K; Tufton N; Akker S; Deinum J; Eisenhofer G; Timmers H; Spaanderman M; Lenders J
BJOG; 2021 Jul; 128(8):1264-1272. PubMed ID: 33342020
[TBL] [Abstract][Full Text] [Related]
13. Pheochromocytoma/Paraganglioma Screening: Low Rates in At-Risk Populations.
Igaz P
J Clin Endocrinol Metab; 2023 May; 108(6):e350-e351. PubMed ID: 36652425
[No Abstract] [Full Text] [Related]
14. Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature.
Bancos I; Atkinson E; Eng C; Young WF; Neumann HPH;
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):13-21. PubMed ID: 33248478
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the diagnosis of pheochromocytoma and paraganglioma syndrome.
Zdrojowy-Wełna A; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2014; 35(5):355-8. PubMed ID: 25275255
[TBL] [Abstract][Full Text] [Related]
16. Acute cardiac complications and subclinical myocardial injuries associated with pheochromocytoma and paraganglioma.
Zhou J; Xuan H; Miao Y; Hu J; Dai Y
BMC Cardiovasc Disord; 2021 Apr; 21(1):203. PubMed ID: 33882857
[TBL] [Abstract][Full Text] [Related]
17. TAKOTSUBO-LIKE CARDIOMYOPATHY IN A LARGE COHORT OF PATIENTS WITH PHEOCHROMOCYTOMA AND PARAGANGLIOMA.
Gagnon N; Mansour S; Bitton Y; Bourdeau I
Endocr Pract; 2017 Oct; 23(10):1178-1192. PubMed ID: 28704094
[TBL] [Abstract][Full Text] [Related]
18. Properly Collected Plasma Metanephrines Excludes PPGL After False-Positive Screening Tests.
Kline GA; Boyd J; Polzin B; Harvey A; Pasieka JL; Sadrzadeh HSM; Leung AA
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2900-e2906. PubMed ID: 33846745
[TBL] [Abstract][Full Text] [Related]
19. Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies.
Schreiner F; Beuschlein F
Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101347. PubMed ID: 31662271
[TBL] [Abstract][Full Text] [Related]
20. Approach to the Patient: Perioperative Management of the Patient with Pheochromocytoma or Sympathetic Paraganglioma.
Berends AMA; Kerstens MN; Lenders JWM; Timmers HJLM
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32726444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
